Pila Pharma AB

ST:PILA Sweden Biotechnology
Market Cap
$3.30 Million
Skr37.04 Million SEK
Market Cap Rank
#34480 Global
#543 in Sweden
Share Price
Skr1.22
Change (1 day)
+3.92%
52-Week Range
Skr1.10 - Skr3.79
All Time High
Skr12.40
About

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more

Pila Pharma AB (PILA) - Total Liabilities

Latest total liabilities as of December 2025: Skr1.43 Million SEK

Based on the latest financial reports, Pila Pharma AB (PILA) has total liabilities worth Skr1.43 Million SEK as of December 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Pila Pharma AB - Total Liabilities Trend (2015–2025)

This chart illustrates how Pila Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Pila Pharma AB Competitors by Total Liabilities

The table below lists competitors of Pila Pharma AB ranked by their total liabilities.

Company Country Total Liabilities
Highway 50 Gold Corp
PINK:HGGCF
USA $665.68K
CopperEx Resources Corporation
V:CUEX
Canada CA$286.39K
Digistar Corporation Bhd
KLSE:0029
Malaysia RM223.59 Million
DONTNOD Entertainment SA
PA:ALDNE
France €12.65 Million
Interpace Biosciences Inc
OTCQX:IDXG
USA $12.33 Million
Tactical Resources Corp.
PINK:USREF
USA $8.61 Million
MBB (MBB.SG)
STU:MBB
Germany €360.23 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Pila Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.26 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pila Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pila Pharma AB (2015–2025)

The table below shows the annual total liabilities of Pila Pharma AB from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 Skr1.43 Million +48.91%
2024-12-31 Skr963.00K -46.33%
2023-12-31 Skr1.79 Million +32.22%
2022-12-31 Skr1.36 Million -10.42%
2021-12-31 Skr1.51 Million -22.20%
2020-12-31 Skr1.95 Million +301.72%
2019-12-31 Skr484.68K -41.04%
2018-12-31 Skr821.98K +46.42%
2017-12-31 Skr561.37K -12.93%
2016-12-31 Skr644.76K +162.19%
2015-12-31 Skr245.91K --